Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral drug
Research
Protease inhibitor outperforms Paxlovid protecting lungs of mice
An oral drug developed by Stanford University researchers may be superior to Pfizer’s Paxlovid at reducing the severity of COVID-19, at least in mice.
Helen Floersh
Mar 14, 2024 6:30am
Enanta halts work on joint hMPV-RSV drug to extend cash to 2027
Nov 21, 2023 8:30am
J&J links antiviral to protection from dengue in challenge trial
Oct 20, 2023 9:30am
Atea dumps dengue drug as forecast R&D timelines, costs spiral
Mar 1, 2023 6:50am
Pfizer's hunt for Paxlovid sibling leads to low-profile biotech
Dec 6, 2022 9:35am
Potential for broad-spectrum antivirals could lie in host cells
Oct 12, 2022 12:21pm